An international, prospective, observational cohort study to assess patient treatment satisfaction, patient-reported outcomes, effectiveness, and safety of a fixed-dose combination of Calcipotriene/Betamethasone Dipropionate PAD cream in the treatment of mild-to-moderate plaque psoriasis of the scalp in adults (PRO-SCALP)
Recruiting
- Conditions
- Scalp Psoriasis
- Registration Number
- DRKS00031464
- Lead Sponsor
- Almirall S.A
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 300
Inclusion Criteria
Patients with mild-to-moderate plaque psoriasis of the scalp (defined as PGA score of 2 or 3 at baseline) with or without involvement of the trunk and limbs, and who may or may not have been previously treated (treatment-naive patients) with other anti-psoriatic therapies; prescribed with Wynzora® treatment according to SmPC in routine clinical practice.
Exclusion Criteria
Patients who are not eligible for treatment with Wynzora® in accordance with the approved product information.
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Absolute TSQM-9 effectiveness, convenience, and global satisfaction domain scores associated with Wynzora® at the end of 8-12 week study observation period
- Secondary Outcome Measures
Name Time Method Among others: <br>- Patient reported outcomes (Scalpdex, WI-NRS, PPQ, CUSP-Q, PSY-SCALP)<br>- Clinician reported outcomes (Scalp-PGA, S-mPASI)<br>- Safety and tolerability of Wynzora® in routine practice